![Pierre Rémy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Pierre Rémy
Fondatore presso
Keensight Capital SAS
Profilo
Pierre Rémy is the founder of Keensight Capital SAS, which was founded in 2013.
He is currently the Chairman of Biovian Oy and a Director at LDR Spine USA, Inc. He previously held positions as a Director at LDR Holding Corp.
and a Member-Supervisory Board at Crossject SA. He will serve as a Member-Supervisory Board at Unifin SAS from 2019 to 2023.
Mr. Rémy holds an MBA from Sciences Po and a graduate degree from Arts Et Metiers Paristech.
Posizioni attive di Pierre Rémy
| Società | Posizione | Inizio |
|---|---|---|
Keensight Capital SAS
 Keensight Capital SAS Investment ManagersFinance Keensight is an active manager which focuses on investments in innovative technologies. They invest in companies based on Information and Communications Technologies, particularly as applied to network throughput improvement, networks interconnectivity and convergence, network safety, data storage management and logistics. They have invested in software companies, semi conductors and telecommunications, as well as in medical technology. Their geographic focus is on Europe and particularly France. The firm favors mature businesses and generally participates in second and subsequent financing rounds. They target companies with proven technology, an already established clientele, a leading market position and high-growth potential. They promote the international expansion of their investee companies. | Fondatore | 01/11/2013 |
LDR Spine USA, Inc.
 LDR Spine USA, Inc. Medical SpecialtiesHealth Technology Offers sterile spinal implant systems | Direttore/Membro del Consiglio | - |
Biovian Oy
 Biovian Oy Pharmaceuticals: MajorHealth Technology Provides contract manufacturing and development of biopharmaceuticals | Presidente | - |
Precedenti posizioni note di Pierre Rémy
| Società | Posizione | Fine |
|---|---|---|
Unifin SAS
 Unifin SAS Medical SpecialtiesHealth Technology Engages in the production and packaging sterile liquids | Direttore/Membro del Consiglio | 16/04/2023 |
| LDR HOLDING CORP | Direttore/Membro del Consiglio | - |
| CROSSJECT | Direttore/Membro del Consiglio | - |
Formazione di Pierre Rémy
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
24
Relazioni di 1° grado
8
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 8 |
|---|---|
LDR Spine USA, Inc.
LDR Spine USA, Inc. Medical SpecialtiesHealth Technology Offers sterile spinal implant systems | Health Technology |
LDR Holding Corp.
 LDR Holding Corp. Medical SpecialtiesHealth Technology Engages in designing and commercializing of novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders | Health Technology |
Crossject SA
 Crossject SA Medical SpecialtiesHealth Technology Designs and develops needle free, pre-filled single-use injection systems | Health Technology |
Sciences Po
 Sciences Po Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Arts Et Metiers Paristech
 Arts Et Metiers Paristech Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight is an active manager which focuses on investments in innovative technologies. They invest in companies based on Information and Communications Technologies, particularly as applied to network throughput improvement, networks interconnectivity and convergence, network safety, data storage management and logistics. They have invested in software companies, semi conductors and telecommunications, as well as in medical technology. Their geographic focus is on Europe and particularly France. The firm favors mature businesses and generally participates in second and subsequent financing rounds. They target companies with proven technology, an already established clientele, a leading market position and high-growth potential. They promote the international expansion of their investee companies. | Finance |
Biovian Oy
Biovian Oy Pharmaceuticals: MajorHealth Technology Provides contract manufacturing and development of biopharmaceuticals | Health Technology |
Unifin SAS
Unifin SAS Medical SpecialtiesHealth Technology Engages in the production and packaging sterile liquids | Health Technology |
